Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156055 | 0.90 | HPGD (0.56) | HPGDGPR88ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL1360839 | 0.84 | TACR1 (0.41) | CTSSCTSKGPR139CTSL | |
| SCHEMBL1361680 | 0.83 | GPR88 (0.44) | GPR88ALDH1A1KDM4ESMN1; SMN2NPSR1 | |
| SCHEMBL1360814 | 0.80 | MMP1 (0.45) | — | |
| SCHEMBL2945634 | 0.80 | MME (0.48) | HPGDALDH1A1MAPK1CTSSCTSK | |
| SCHEMBL1362526 | 0.78 | CTSS (0.41) | CYP1A2SMN1; SMN2NPSR1CTSSCTSK | |
| SCHEMBL4813221 | 0.78 | CTSS (0.57) | GPR88CTSSCTSKCTSL | |
| SCHEMBL1362207 | 0.78 | HTRA1 (0.44) | CTSSCTSK | |
| SCHEMBL1363046 | 0.78 | MEN1 (0.35) | GPR88CTSSCTSKGPR139CTSL | |
| SCHEMBL1362244 | 0.76 | CYP3A4 (0.47) | ALDH1A1KDM4ECTSSCTSKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501813-B1 | Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them | ALBIREO AB (SE) | 2013-08-14 | — | — | EP | disclosed |
| US-8067584-B2 | Benzothiazepine derivatives | ALBIREO AB (SE) | 2011-11-29 | — | — | US | disclosed |
| US-7238684-B2 | Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7192946-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-20060094884-A1 | Benzothiazepine and benzothiepine derivatives | ALBIREO AB (SE) | 2006-05-04 | — | — | US | disclosed |
| EP-1597245-A1 | BENZOTHIAZEPINE AND BENZOTHIEPINE DERIVATIVES | AstraZeneca AB (SE) | 2005-11-23 | — | — | EP | disclosed |
| US-20050143368-A1 | Chemical compounds | ALBIREO AB (SE) | 2005-06-30 | — | — | US | disclosed |
| EP-1501813-A2 | BENZOTHIADIAZEPINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Astrazeneca AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| US-20040254160-A1 | Benzothiazepine derivatives | ELOBIX AB (SE) | 2004-12-16 | — | — | US | disclosed |
| WO-2004076430-A1 | BENZOTHIAZEPINE AND BENZOTHIEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-09-10 | — | — | WO | disclosed |
| EP-1430040-A1 | BENZOTHIAZEPINE DERIVATIVES | Astrazeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003091232-A2 | BENZOTHIADIAZEPINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003020710-A1 | BENZOTHIAZEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143368-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | HPGD 2157/4885GPR88 724/4885ALDH1A1 1675/4885 |
| US-20040254160-A1 | Benzothiazepine derivatives | SLC10A2, SLC10A1, ABCB11 | HPGD 1399/4885GPR88 577/4885ALDH1A1 941/4885 |
| US-20060094884-A1 | Benzothiazepine and benzothiepine derivatives | SLC10A2, SLC10A1, ABCB11 | HPGD 1518/4885GPR88 1023/4885ALDH1A1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.